← Back to Search
CAR T-cell Therapy
Gene Therapy for Acute Lymphoblastic Leukemia
Denver, CO
Phase 1 & 2
Recruiting
Research Sponsored by Vironexis Biotherapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Relapsed B-cell ALL with bone marrow blasts >= 5%
Refractory B-cell ALL as defined in the protocol
Must not have
Acute Graft versus Host Disease (GvHD): Grade 2-4 or chronic GvHD of any grade
History of thrombotic microangiopathy or cardiomyopathy, or evidence of sensory neuropathy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new treatment called VNX-101 in patients with a type of leukemia called B-cell acute lymphoblastic leukemia. The trial is focusing on evaluating the safety and effectiveness of V
See full description
Who is the study for?
This trial is for adults and teens with B-cell acute lymphoblastic leukemia that has come back or hasn't responded to treatment. They should have a certain amount of cancer cells in their bone marrow, can't be treated with CAR-T therapy or didn't improve after it, and must meet specific health criteria for major organs and blood.Check my eligibility
What is being tested?
The study tests different doses of VNX-101, a gene therapy drug, to see how safe it is and how well it works against leukemia. It's an early-stage trial where patients receive increasing amounts of the drug to find the best dose.See study design
What are the potential side effects?
As this is a first-in-human study for VNX-101, potential side effects are not fully known but may include reactions at the infusion site, flu-like symptoms, changes in blood counts leading to increased infection risk or bleeding problems.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My leukemia has returned and more than 5% of my bone marrow cells are cancerous.
show original
Select...
My B-cell ALL does not respond to standard treatments.
show original
Select...
I cannot or chose not to receive CAR-T therapy, or it did not work for me.
show original
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have moderate to severe acute GvHD or any grade of chronic GvHD.
show original
Select...
I have a history of blood vessel or heart muscle disease, or nerve damage.
show original
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Group 1/Group 2/Group 3/Group 4Experimental Treatment4 Interventions
Find a Location
Closest Location:Oncology Hematology Care· Cincinnati, OH· 48 miles
Who is running the clinical trial?
Vironexis Biotherapeutics Inc.Lead Sponsor
Vironexis Clinical TrialsStudy DirectorVironexis Biotherapeutics Inc.